ReviewInfectious disease reports2025
Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives.
Review in Infectious disease reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- New antifungal and less toxic zwitterionic derivatives of 26-membered polyene antibiotic - pimaricin containingJournal of enzyme inhibition and medicinal chemistry · 2026Article
- Fosmanogepix: A comprehensive review of its origin, mechanism, antifungal efficacy, and resistance (Review).Biomedical reports · 2026Review
- Antifungal Dispensing in Denmark: Patterns Across Primary Care, Secondary Care, and Over-the-Counter Sectors.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- RethinkingVaccines · 2026Review
- A review on fungal pathogens in the One Health framework: connecting plant, animal, and human health.Archives of microbiology · 2026Review
- COVID-19-Associated Fungal Co-Infections: Pathogenesis, Diagnostics, Biomarkers, and Therapeutic Strategies.Journal of clinical medicine · 2026Review
- TRIZ-guided computational innovation framework for the automated generation and prioritization of novel azole-like antifungal candidates targeting Candida auris CYP51.Journal of computer-aided molecular design · 2026Article
- The BRCT domain enhances DNA binding and catalytic efficiency of fungal PARPs.Nature communications · 2026Article
- Dermatophytosis: An Update on Global Epidemiology.Journal of fungi (Basel, Switzerland) · 2026Review
- Antifungal Activity of a Postbiotic Cell-free Supernatant of Lactiplantibacillus plantarum from Pulicaria jaubertii against Aspergillus fumigatus and Candida albicans.BMC complementary medicine and therapies · 2026Article
- Clinical Significance of Intestinal Fungal Overgrowth: Integrating the Gut Mycobiome into Modern Gastroenterology.Microorganisms · 2026Review
- A cyanobacteria-mediated TiO₂ nanoparticle and propolis cream enhances antifungal activity and wound healing against Candida albicans in mice.Scientific reports · 2026Article
- Anti-Candida albicans effect of the new antifungal compound Venetin-1 obtained from earthworms versus amphotericin B.Scientific reports · 2026Article
- Identification of GPI-Anchored Wall Transfer Protein 1 Modulators for Fungal Infections Through Generative AI and Physics-Based Approaches.International journal of molecular sciences · 2026Article
- The dual role of azoles: lifesaving antifungals and drivers of resistance - a One Health perspective.Nature communications · 2026Review
- New and Investigational Treatment Options for Dermatomycosis in the Era of Antifungal Resistance.Journal of fungi (Basel, Switzerland) · 2026Review
- Antifungal activity of isolated compounds from CTurkish journal of chemistry · 2026Article
- The structural language of fungal cell wall sugars in WHO priority fungi: the determinant of pathogenicity and the gateway to new therapies.Frontiers in immunology · 2026Review
- Rational Design and Optimization of MCh-AMP1: A Stable α-Helical Antifungal Peptide with Enhanced Activity AgainstDrug design, development and therapy · 2026Article
- Structural barriers to antifungal drug development.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive fungal infections (IFIs) represent a growing global health threat, particularly for immunocompromised populations, with mortality exceeding 1.5 million deaths annually. Despite their clinical and economic burden-costing billions in healthcare expenditures-fungal infections remain underprioritized in public health agendas. This review examines the current landscape of antifungal therapy, focusing on advances, challenges, and future directions. Key drug classes (polyenes, azoles, echinocandins, and novel agents) are analyzed for their mechanisms of action, pharmacokinetics, and clinical applications, alongside emerging resistance patterns in pathogens like
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.